Press Release Details
InVivo Therapeutics Urges All Stockholders to Vote at the 2021 Annual Meeting to Be Held on Friday July 16, 2021
Calls for All Stockholders to Vote and to Vote in Favor of the Proxy Proposals
Stockholders holding common stock at the close of business on
InVivo is also asking stockholders to follow their Board of Directors’ recommendation to vote FOR all proposals, including the election of directors, increase in authorized shares of common stock, authorization of shares of “blank-check” preferred stock, an amendment to the 2015 Equity Incentive Plan and ratification of independent registered public accounting firm. The Board of Directors believes that Proposal #2, the increase in authorized common shares, will enable InVivo to engage in capital raising transactions and other strategic transactions involving the issuance of equity securities. Although InVivo has no specific current plans to issue shares of common stock, it has limited capital, and to execute on its business plan and remain viable as a going concern, it must have the flexibility to engage in capital raising transactions until it is able to generate sufficient revenue and cash flow. Increasing the number of authorized shares of common stock will enable InVivo to issue common stock or securities convertible or exercisable into common stock to investors and other strategic partners.
For questions relating to the voting of shares or to request additional or misplaced proxy voting materials, please contact the Company’s proxy solicitors,
A copy of the Company's proxy statement as previously filed with the
YOUR PARTICIPATION IS IMPORTANT – PLEASE VOTE TODAY!
About
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect” and similar expressions, and include statements about the impact of the proxy proposals on the Company’s operations. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to successfully enroll additional patients; the impact of the COVID-19 pandemic on the Company’s operations, including its clinical trials; the timing of the
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005048/en/
Investor Contact:
CORE IR
brets@coreir.com
(516) 222-2560
Media Contact
Ten
gina@tenbridgecommunications.com
Source: